ATS 2017

May 26, 2017May 26, 2017

Ofev Doubles the Chance of Improving or Stabilizing IPF, Studies Find

Idiopathic pulmonary fibrosis (IPF) patients treated with Ofev (nintedanib) are twice as likely to improve or see their disease stabilize than untreated patients, according to a pool of data from ... Read more

May 25, 2017May 25, 2017

Esbriet Subgroup Analyses Suggest Benefits Also in Moderate and Severe IPF

Idiopathic Pulmonary Fibrosis, News

Patients with more severe idiopathic pulmonary fibrosis (IPF) also benefit from Esbriet (pirfenidone) treatment, as do IPF patients with moderate lung function impairment, according to two studies presented at the ... Read more

May 24, 2017June 19, 2017

INOpulse Nitric Oxide System Seen to Treat PH Patients with IPF and COPD Symptoms

COPD, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

The INOpulse nitric oxide delivery system met its primary Phase 2 clinical trial goal of increasing the blood-vessel volume of pulmonary hypertension patients with idiopathic pulmonary fibrosis (PH-IPF), according to its maker, Bellerophon Therapeutics. ... Read more

May 23, 2017May 23, 2017

Adding Noninvasive Ventilator to At-home Oxygen Therapy Benefits COPD Patients

COPD, News

Adding a noninvasive ventilator to home oxygen therapy prolonged the time to hospital readmission for patients with chronic obstructive pulmonary disease (COPD) after an acute exacerbation. The study with the findings, ... Read more

May 22, 2017May 22, 2017

Galecto’s Inhaled IPF Therapy Candidate Shows Early Promise in Clinical Trial

Idiopathic Pulmonary Fibrosis, News

Inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients, Galecto Biotech reports. The results came from a Phase 1b/2a clinical trial (NCT02257177) evaluating TD139 in two parts. Phase 1b was ... Read more

May 19, 2017May 19, 2017

Resokine Protein Key to Regulating Inflammation and Fibrosis in Lung Disease, Study Reports

Idiopathic Pulmonary Fibrosis, News

Results from preclinical studies showed that restoring the levels of a protein called Resokine has therapeutic potential for the treatment of severe, rare pulmonary diseases characterized by inflammation and fibrosis, ... Read more

May 12, 2017May 12, 2017

Genomic Classifiers Shown to Improve Diagnosis of Lung Cancer and IPF, Veracyte Says

Idiopathic Pulmonary Fibrosis, Lung Cancer, News

Multiple studies’ data support the use of Veracyte’s genomic classifiers to improve the diagnosis of lung cancer and idiopathic pulmonary fibrosis (IPF), the company reports. The data will be presented ... Read more

March 16, 2017March 16, 2017

Galecto’s TD139 Shows Promise in IPF Patients, Clinical Trial Shows

Idiopathic Pulmonary Fibrosis, News

Galecto Biotech has completed a Phase 1b/2a clinical trial that indicated its inhaled therapy candidate TD139 shows promise in treating idiopathic pulmonary fibrosis (IPF) patients. TD139 is an inhibitor of galectin-3, ... Read more